{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:39:04Z","timestamp":1794098344546,"version":"4.8.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A2C3006305"],"award-info":[{"award-number":["2019R1A2C3006305"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI19C0753"],"award-info":[{"award-number":["HI19C0753"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tamoxifen resistance remains a significant obstacle in oestrogen receptor (ER)-positive breast cancer. The function of absent, small, or homeotic 2-like protein (ASH2L) at chr8p11.23 in breast cancer is not entirely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Survival analysis according to ASH2L expression was examined using METABRIC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009968) and KM plotter (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009150). ASH2L-mediated tamoxifen resistance and CSC activity were evaluated through in vitro assays, including SRB, colony formation, tumour sphere formation, and FACS, and in vivo xenograft models. RNA-seq and ChIP-qPCR were performed to elucidate the underlying mechanism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High ASH2L amplification correlated with poor prognosis in tamoxifen-treated ER-positive breast cancer patients. ASH2L induces tamoxifen resistance and promotes CSC activity through ITGA6\/ERK signalling in an H3K4me3-dependent manner. Mechanistically, ASH2L is recruited to HIF2A and ITGA6 promoters, enhancing H3K4me3 and H3K27ac and reducing HDAC1 and H3K27me3, thereby activating ERK signalling. Genetic or pharmacological inhibition of ASH2L, ITGA6, or ERK abolished ASH2L-induced CSC activity. Although ERK inhibition alone did not rescue tamoxifen resistance, its combination with tamoxifen overcame resistance in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ASH2L promotes tamoxifen resistance and CSC activity through ITGA6\/ERK signalling. Combination therapy with tamoxifen and an ERK inhibitor may be a promising strategy for ER-positive breast cancer patients with ASH2L overexpression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03347-8","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:47:44Z","timestamp":1771926464000},"page":"1150-1165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6\/ERK signaling in ER-positive breast cancer"],"prefix":"10.1038","volume":"134","author":[{"given":"Young-Hyeon","family":"Kye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Jeong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hea-Ry","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tack-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Yun","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Kyung","family":"Myung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9206-8210","authenticated-orcid":false,"given":"Gu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"3347_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/gtmb.2021.0286","volume":"26","author":"MA Mart\u00ednez-Sifuentes","year":"2022","unstructured":"Mart\u00ednez-Sifuentes MA, Bassol-Mayagoitia S, Nava-Hern\u00e1ndez MP, Ruiz-Flores P, Ramos-Trevi\u00f1o J, Haro-Santa cruz J, et al. Survivin in breast cancer: a review. Genet Test Mol Biomark. 2022;26:411\u201321.","journal-title":"Genet Test Mol Biomark"},{"key":"3347_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3347_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.18.00440","volume":"37","author":"T Ruhstaller","year":"2019","unstructured":"Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertsen B, de Azambuja E, et al. Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor\u2013positive breast cancer: long-term follow-up of the BIG 1-98 trial. J Clin Oncol. 2019;37:105.","journal-title":"J Clin Oncol"},{"key":"3347_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.37349\/etat.2022.00096","volume":"3","author":"D Musheyev","year":"2022","unstructured":"Musheyev D, Alayev A. Endocrine therapy resistance: what we know and future directions. Explor Target Antitumor Ther. 2022;3:480.","journal-title":"Explor Target Antitumor Ther"},{"key":"3347_CR5","doi-asserted-by":"crossref","unstructured":"Soares De Pinho I, Marques C, Fernandes Gomes I, Casimiro S, Pacheco T, Sousa RTd, et al. Exploring new pathways in endocrine-resistant breast cancer. Explor Target Antitumor Ther. 2022;3:337\u201361.","DOI":"10.37349\/etat.2022.00086"},{"key":"3347_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.07.002","volume":"151","author":"S Winters","year":"2017","unstructured":"Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1\u201332.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"3347_CR7","doi-asserted-by":"crossref","unstructured":"Crawford BD, Hess JL. MLL core components give the green light to histone methylation. ACS Chem Biol. 2006;1:95\u20138.","DOI":"10.1021\/cb600367v"},{"key":"3347_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nsmb.2093","volume":"18","author":"S Sarvan","year":"2011","unstructured":"Sarvan S, Avdic V, Tremblay V, Chaturvedi C-P, Zhang P, Lanouette S, et al. Crystal structure of the trithorax group protein ASH2L reveals a forkhead-like DNA binding domain. Nat Struct Mol Biol. 2011;18:857\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"3347_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/bfgp\/els017","volume":"11","author":"P Ernst","year":"2012","unstructured":"Ernst P, Vakoc CR. WRAD: enabler of the SET1-family of H3K4 methyltransferases. Brief Funct Genom. 2012;11:217\u201326.","journal-title":"Brief Funct Genom"},{"key":"3347_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-biochem-051710-134100","volume":"81","author":"A Shilatifard","year":"2012","unstructured":"Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem. 2012;81:65.","journal-title":"Annu Rev Biochem"},{"key":"3347_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cell.2017.08.002","volume":"171","author":"B Schuettengruber","year":"2017","unstructured":"Schuettengruber B, Bourbon H-M, Di Croce L, Cavalli G. Genome regulation by polycomb and trithorax: 70 years and counting. Cell. 2017;171:34\u201357.","journal-title":"Cell"},{"key":"3347_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/bib\/bbz003","volume":"21","author":"HY Kim","year":"2020","unstructured":"Kim HY, Choi HJ, Lee JY, Kong G. Cancer Target Gene Screening: a web application for breast cancer target gene screening using multi-omics data analysis. Brief Bioinform. 2020;21:663\u201375.","journal-title":"Brief Bioinform"},{"key":"3347_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbrc.2023.05.061","volume":"669","author":"G Batbayar","year":"2023","unstructured":"Batbayar G, Ishimura A, Lyu H, Wanna-Udom S, Meguro-Horike M, Terashima M, et al. ASH2L, a COMPASS core subunit, is involved in the cell invasion and migration of triple-negative breast cancer cells through the epigenetic control of histone H3 lysine 4 methylation. Biochem Biophys Res Commun. 2023;669:19\u201329.","journal-title":"Biochem Biophys Res Commun"},{"key":"3347_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/00220345231207309","volume":"103","author":"X Zhu","year":"2024","unstructured":"Zhu X, Ma Z, Xie F, Wang J. ASH2L, Core subunit of H3K4 methylation complex, regulates amelogenesis. J Dent Res. 2024;103:81\u201390.","journal-title":"J Dent Res"},{"key":"3347_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1116805","volume":"11","author":"P Costa","year":"2023","unstructured":"Costa P, Sales SLA, Pinheiro DP, Pontes LQ, Maranhao SS, Pessoa CDO, et al. Epigenetic reprogramming in cancer: from diagnosis to treatment. Front Cell Dev Biol. 2023;11:1116805.","journal-title":"Front Cell Dev Biol"},{"key":"3347_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.semcancer.2020.07.015","volume":"83","author":"ME Neganova","year":"2022","unstructured":"Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. Semin Cancer Biol. 2022;83:452\u201371.","journal-title":"Semin Cancer Biol"},{"key":"3347_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s11658-022-00344-6","volume":"27","author":"M Karami Fath","year":"2022","unstructured":"Karami Fath M, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari Oryani M, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022;27:52.","journal-title":"Cell Mol Biol Lett"},{"key":"3347_CR18","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzman","year":"2014","unstructured":"Guzman C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE. 2014;9:e92444.","journal-title":"PLoS ONE"},{"key":"3347_CR19","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948058","volume":"20","author":"HJ Choi","year":"2019","unstructured":"Choi HJ, Jin S, Cho H, Won HY, An HW, Jeong GY, et al. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. EMBO Rep. 2019;20:e48058.","journal-title":"EMBO Rep"},{"key":"3347_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118729","volume":"264","author":"IA Voutsadakis","year":"2021","unstructured":"Voutsadakis IA. Amplification of 8p11.23 in cancers and the role of amplicon genes. Life Sci. 2021;264:118729.","journal-title":"Life Sci"},{"key":"3347_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/0008-5472.CAN-20-0360","volume":"81","author":"G-Y Jeong","year":"2021","unstructured":"Jeong G-Y, Park MK, Choi H-J, An HW, Park Y-U, Choi H-J, et al. NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progressionepigenetic regulation of breast cancer progression by NSD3. Cancer Res. 2021;81:77\u201390.","journal-title":"Cancer Res"},{"key":"3347_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature15736","volume":"528","author":"C Cancer Cell Line Encyclopedia","year":"2015","unstructured":"Cancer Cell Line Encyclopedia C, Genomics OF, Drug Sensitivity IN, Cancer C. Pharmacogenomic agreement between two cancer cell line data sets. Nature. 2015;528:84\u20137.","journal-title":"Nature"},{"key":"3347_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"3347_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2019.194475","volume":"1863","author":"L Rocha-Viegas","year":"2020","unstructured":"Rocha-Viegas L, Silbermins M, Ogara MF, Pellegrini JM, Nu\u00f1ez SY, Garc\u00eda VE, et al. Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells. Biochim Biophys Acta Gene Regul Mech. 2020;1863:194475.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"3347_CR25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/onc.2014.198","volume":"34","author":"SK Mungamuri","year":"2015","unstructured":"Mungamuri SK, Wang S, Manfredi JJ, Gu W, Aaronson SA. Ash2L enables P53-dependent apoptosis by favoring stable transcription pre-initiation complex formation on its pro-apoptotic target promoters. Oncogene. 2015;34:2461\u201370.","journal-title":"Oncogene"},{"key":"3347_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41576-020-0278-0","volume":"22","author":"BK Cenik","year":"2021","unstructured":"Cenik BK, Shilatifard A. COMPASS and SWI\/SNF complexes in development and disease. Nat Rev Genet. 2021;22:38\u201358.","journal-title":"Nat Rev Genet"},{"key":"3347_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0510-x","volume":"15","author":"DL Brooks","year":"2016","unstructured":"Brooks DL, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, et al. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer. 2016;15:26.","journal-title":"Mol Cancer"},{"key":"3347_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep33376","volume":"6","author":"T Hu","year":"2016","unstructured":"Hu T, Zhou R, Zhao Y, Wu G. Integrin alpha6\/Akt\/Erk signaling is essential for human breast cancer resistance to radiotherapy. Sci Rep. 2016;6:33376.","journal-title":"Sci Rep"},{"key":"3347_CR29","doi-asserted-by":"crossref","unstructured":"Rocca A, Braga L, Volpe MC, Maiocchi S, Generali D. The predictive and prognostic role of Ras-Raf-MEK-ERK pathway alterations in breast cancer: revision of the literature and comparison with the analysis of cancer genomic datasets. Cancers. 2022;14:5306.","DOI":"10.3390\/cancers14215306"},{"key":"3347_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati V, Mahapatra DK, Bharti SK. PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314\u201341.","journal-title":"Eur J Med Chem"},{"key":"3347_CR31","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.apsb.2021.01.004","volume":"11","author":"M Li","year":"2021","unstructured":"Li M, Wang Y, Li M, Wu X, Setrerrahmane S, Xu H. Integrins as attractive targets for cancer therapeutics. Acta Pharm Sin B. 2021;11:2726\u201337.","journal-title":"Acta Pharm Sin B"},{"key":"3347_CR32","doi-asserted-by":"crossref","unstructured":"Waris G, Hafeez S, Urooj M, Saleem S, Gillani Z, Shaheen S, et al. BAD, a proapoptotic protein, escapes ERK\/RSK phosphorylation in deguelin and siRNA-treated HeLa cells. PLoS ONE. 2016;11:e0145780.","DOI":"10.1371\/journal.pone.0145780"},{"key":"3347_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0","volume":"79","author":"MJ Boucher","year":"2000","unstructured":"Boucher MJ, Morisset J, Vachon PH, Reed JC, Lain\u00e9 J, Rivard N. MEK\/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2000;79:355\u201369.","journal-title":"J Cell Biochem"},{"key":"3347_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/jcp.27013","volume":"234","author":"PS Campbell","year":"2018","unstructured":"Campbell PS, Mavingire N, Khan S, Rowland LK, Wooten JV, Opoku-Agyeman A, et al. AhR ligand aminoflavone suppresses alpha6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells. J Cell Physiol. 2018;234:108\u201321.","journal-title":"J Cell Physiol"},{"key":"3347_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.946811","volume":"13","author":"J Feng","year":"2022","unstructured":"Feng J, Meng X. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: fundamentals and beyond. Front Pharm. 2022;13:946811.","journal-title":"Front Pharm"},{"key":"3347_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-021-01041-1","volume":"14","author":"GJ Yang","year":"2021","unstructured":"Yang GJ, Zhu MH, Lu XJ, Liu YJ, Lu JF, Leung CH, et al. The emerging role of KDM5A in human cancer. J Hematol Oncol. 2021;14:30.","journal-title":"J Hematol Oncol"},{"key":"3347_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4161\/trns.20496","volume":"3","author":"S Bianco","year":"2012","unstructured":"Bianco S, Gevry N. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms. Transcription. 2012;3:165\u201370.","journal-title":"Transcription"},{"key":"3347_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15146","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Yu B, Deng P, Cheng Y, Yu Y, Kevork K, et al. KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt\/beta-catenin signalling. Nat Commun. 2017;8:15146.","journal-title":"Nat Commun"},{"key":"3347_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13046-021-02119-x","volume":"40","author":"R Wang","year":"2021","unstructured":"Wang R, Liu J, Li K, Yang G, Chen S, Wu J, et al. An SETD1A\/Wnt\/beta-catenin feedback loop promotes NSCLC development. J Exp Clin Cancer Res. 2021;40:318.","journal-title":"J Exp Clin Cancer Res"},{"key":"3347_CR40","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1038\/s41388-020-01449-y","volume":"39","author":"X Leng","year":"2020","unstructured":"Leng X, Wang J, An N, Wang X, Sun Y, Chen Z. Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3. Oncogene. 2020;39:6468\u201379.","journal-title":"Oncogene"},{"key":"3347_CR41","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.7150\/thno.72599","volume":"12","author":"ML Jin","year":"2022","unstructured":"Jin ML, Yang L, Jeong KW. SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor alpha-positive breast cancer cells. Theranostics. 2022;12:5761\u201375.","journal-title":"Theranostics"},{"key":"3347_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/jnci\/djx207","volume":"110","author":"H-J Choi","year":"2018","unstructured":"Choi H-J, Joo H-S, Won H-Y, Min K-W, Kim H-Y, Son T, et al. Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2018;110:400\u201310.","journal-title":"J Natl Cancer Inst"},{"key":"3347_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10549-010-1304-2","volume":"130","author":"NT Phuong","year":"2011","unstructured":"Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, et al. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2011;130:73\u201383.","journal-title":"Breast Cancer Res Treat"},{"key":"3347_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1158\/0008-5472.CAN-17-1327","volume":"78","author":"Y Wu","year":"2018","unstructured":"Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, et al. Tamoxifen resistance in breast cancer is regulated by the EZH2-ERalpha-GREB1 transcriptional axis. Cancer Res. 2018;78:671\u201384.","journal-title":"Cancer Res"},{"key":"3347_CR45","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","volume":"52","author":"G Xu","year":"2020","unstructured":"Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet. 2020;52:198\u2013207.","journal-title":"Nat Genet"},{"key":"3347_CR46","doi-asserted-by":"publisher","first-page":"31373","DOI":"10.1074\/jbc.M114.579839","volume":"289","author":"J Qi","year":"2014","unstructured":"Qi J, Huo L, Zhu YT, Zhu YJ. Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor alpha gene through GATA-binding protein 3 (GATA3). J Biol Chem. 2014;289:31373\u201381.","journal-title":"J Biol Chem"},{"key":"3347_CR47","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.7150\/thno.34874","volume":"9","author":"G Jiang","year":"2019","unstructured":"Jiang G, Wang X, Sheng D, Zhou L, Liu Y, Xu C, et al. Cooperativity of co-factor NR2F2 with pioneer factors GATA3, FOXA1 in promoting ERalpha function. Theranostics. 2019;9:6501\u201316.","journal-title":"Theranostics"},{"key":"3347_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0960-0760(02)00151-6","volume":"82","author":"LA deGraffenried","year":"2002","unstructured":"deGraffenried LA, Hilsenbeck SG, Fuqua SA. Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol. 2002;82:7\u201318.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3347_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0126-6","volume":"5","author":"MJ Nixon","year":"2019","unstructured":"Nixon MJ, Formisano L, Mayer IA, Estrada MV, Gonzalez-Ericsson PI, Isakoff SJ, et al. PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. NPJ Breast Cancer. 2019;5:31.","journal-title":"NPJ Breast Cancer"},{"key":"3347_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1192-x","volume":"15","author":"JH Chiu","year":"2017","unstructured":"Chiu JH, Wen CS, Wang JY, Hsu CY, Tsai YF, Hung SC, et al. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers. J Transl Med. 2017;15:97.","journal-title":"J Transl Med"},{"key":"3347_CR51","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4161\/epi.23790","volume":"8","author":"E Hervouet","year":"2013","unstructured":"Hervouet E, Cartron PF, Jouvenot M, Delage-Mourroux R. Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics. 2013;8:237\u201345.","journal-title":"Epigenetics"},{"key":"3347_CR52","doi-asserted-by":"crossref","unstructured":"Khademi R, Malekzadeh H, Bahrami S, Saki N, Khademi R, Villa-Diaz LG. Regulation and functions of alpha6-Integrin (CD49f) in cancer biology. Cancers. 2023;15:3466.","DOI":"10.3390\/cancers15133466"},{"key":"3347_CR53","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2174\/1574888X13666181002151330","volume":"14","author":"GD Bigoni-Ordonez","year":"2019","unstructured":"Bigoni-Ordonez GD, Czarnowski D, Parsons T, Madlambayan GJ, Villa-Diaz LG. Integrin alpha6 (CD49f), the microenvironment and cancer stem cells. Curr Stem Cell Res Ther. 2019;14:428\u201336.","journal-title":"Curr Stem Cell Res Ther"},{"key":"3347_CR54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","volume":"35","author":"J Cooper","year":"2019","unstructured":"Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35:347\u201367.","journal-title":"Cancer Cell"},{"key":"3347_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153854","volume":"233","author":"MZ Koh","year":"2022","unstructured":"Koh MZ, Ho WY, Yeap SK, Ali NM, Yong CY, Boo L, et al. Exosomal-microRNA transcriptome profiling of Parental and CSC-like MDA-MB-231 cells in response to cisplatin treatment. Pathol Res Pract. 2022;233:153854.","journal-title":"Pathol Res Pract"},{"key":"3347_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1898-1","volume":"10","author":"A Herreros-Pomares","year":"2019","unstructured":"Herreros-Pomares A, de-Maya-Girones JD, Calabuig-Farinas S, Lucas R, Martinez A, Pardo-Sanchez JM, et al. Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. Cell Death Dis. 2019;10:660.","journal-title":"Cell Death Dis"},{"key":"3347_CR57","doi-asserted-by":"publisher","first-page":"e6345","DOI":"10.1097\/MD.0000000000006345","volume":"96","author":"L Wei","year":"2017","unstructured":"Wei L, Yin F, Zhang W, Li L. STROBE-compliant integrin through focal adhesion involve in cancer stem cell and multidrug resistance of ovarian cancer. Medicine. 2017;96:e6345.","journal-title":"Medicine"},{"key":"3347_CR58","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1016\/j.ymthe.2018.08.018","volume":"26","author":"S Xie","year":"2018","unstructured":"Xie S, Yu X, Li Y, Ma H, Fan S, Chen W, et al. Upregulation of lncRNA ADAMTS9-AS2 promotes salivary adenoid cystic carcinoma metastasis via PI3K\/Akt and MEK\/Erk signaling. Mol Ther. 2018;26:2766\u201378.","journal-title":"Mol Ther"},{"key":"3347_CR59","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1038\/onc.2017.177","volume":"36","author":"K Zhang","year":"2017","unstructured":"Zhang K, Myllymaki SM, Gao P, Devarajan R, Kytola V, Nykter M, et al. Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with alphaV-Class integrins to promote EMT. Oncogene. 2017;36:5681\u201394.","journal-title":"Oncogene"},{"key":"3347_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.yexcr.2019.03.022","volume":"379","author":"Y Wu","year":"2019","unstructured":"Wu Y, Tan X, Liu P, Yang Y, Huang Y, Liu X, et al. ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. Exp Cell Res. 2019;379:30\u201347.","journal-title":"Exp Cell Res"},{"key":"3347_CR61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3347_CR62","doi-asserted-by":"crossref","unstructured":"Naeem M, Iqbal MO, Khan H, Ahmed MM, Farooq M, Aadil MM, et al. A review of twenty years of research on the regulation of signaling pathways by natural products in breast cancer. Molecules. 2022;27:3412.","DOI":"10.3390\/molecules27113412"},{"key":"3347_CR63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123\u201354.","journal-title":"Semin Cancer Biol"},{"key":"3347_CR64","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.3390\/cancers14215306","volume":"14","author":"A Rocca","year":"2022","unstructured":"Rocca A, Braga L, Volpe MC, Maiocchi S, Generali D. The predictive and prognostic role of RAS\u2013RAF\u2013MEK\u2013ERK pathway alterations in breast cancer: revision of the literature and comparison with the analysis of cancer genomic datasets. Cancers. 2022;14:5306.","journal-title":"Cancers"},{"key":"3347_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101046","volume":"14","author":"AB Bhatt","year":"2021","unstructured":"Bhatt AB, Wright TD, Barnes V, Chakrabarty S, Matossian MD, Lexner E, et al. Diverse and converging roles of ERK1\/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer. Transl Oncol. 2021;14:101046.","journal-title":"Transl Oncol"},{"key":"3347_CR66","doi-asserted-by":"crossref","unstructured":"Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E, et al. Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. Int J Mol Sci. 2020;21:3528.","DOI":"10.3390\/ijms21103528"},{"key":"3347_CR67","doi-asserted-by":"crossref","unstructured":"Vafeiadou V, Hany D, Picard D. Hyperactivation of MAPK induces tamoxifen resistance in SPRED2-deficient eralpha-positive breast cancer. Cancers. 2022;14:954.","DOI":"10.3390\/cancers14040954"},{"key":"3347_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115233","volume":"204","author":"L Wester","year":"2022","unstructured":"Wester L, Venneker S, Hazenoot M, Pont C, Koedoot E, Timmermans AM, et al. A kinase inhibitor screen reveals MEK1\/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERalpha-positive luminal breast cancer. Biochem Pharm. 2022;204:115233.","journal-title":"Biochem Pharm"},{"key":"3347_CR69","doi-asserted-by":"publisher","first-page":"103167","DOI":"10.18632\/oncotarget.21704","volume":"8","author":"J Zhou","year":"2017","unstructured":"Zhou J, Zhao T, Ma L, Liang M, Guo YJ, Zhao LM. Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K\/Akt\/mTOR, STAT3 and ERK signaling. Oncotarget. 2017;8:103167\u201381.","journal-title":"Oncotarget"},{"key":"3347_CR70","doi-asserted-by":"publisher","first-page":"44295","DOI":"10.18632\/oncotarget.17869","volume":"8","author":"C Ning","year":"2017","unstructured":"Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, et al. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. 2017;8:44295\u2013311.","journal-title":"Oncotarget"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03347-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03347-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03347-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:02:31Z","timestamp":1774864951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03347-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,20]]}},"alternative-id":["3347"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03347-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Hanyang University (approval number: HY-IACUC-23-0002, HY-IACUC-23-0013, HY-IACUC-23-0014, HY-IACUC-23-0017, HY-IACUC-24-0004) and were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}